Kiniksa Pharmaceuticals KNSA
Kiniksa Pharmaceuticals (Nasdaq: KNSA) is a cardio-renal-metabolic drug developer. Its lead program, KPL-387, is in Phase 3 for recurrent pericarditis. Its next catalyst on record is KPL-1161: Kiniksa expects to initiate a Phase 1 first-in-human trial of KPL-1161 by the end of 2026. (2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: KPL-1161 — Kiniksa expects to initiate a Phase 1 first-in-human trial of KPL-1161 by the end of 2026. (2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| ARCALYST | recurrent pericarditis | protein/peptide | Approved |
| KPL-387 | recurrent pericarditis | antibody | Phase 3 |
| abiprubart | autoimmune diseases (CD40-CD154 inhibitor) | antibody | Phase 2 |
| KPL-1161 | inflammatory conditions (IL-1R1 inhibitor) | antibody | Pre-clinical |
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.